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Background. Staphylococcus aureus bloodstream infection (SABSI) arising from a urinary tract source (UTS) is poorly 
understood.
Methods. We conducted a retrospective analysis in 3 major teaching hospitals in Spain of prospectively collected data of hos-
pitalized patients with SABSI. SABSI-UTS was diagnosed in patients with urinary tract symptoms and/or signs, no evidence of an 
extra-urinary source of infection, and a urinary S. aureus count of ≥105 cfu/mL. Susceptibility of S. aureus strains and patient mor-
tality were compared between SABSI from UTS (SABSI-UTS) and other sources (SABSI-other).
Results. Of 4181 episodes of SABSI, we identified 132 (3.16%) cases of SABSI-UTS that occurred predominantly in patients 
who were male, had high Charlson comorbidity scores, were dependent for daily life activities, and who had undergone urinary 
catheterization and/or urinary manipulation before the infection. SABSI-UTS was more often caused by MRSA strains compared 
with SABSI-other (40.9% vs 17.5%; P < .001). Patients with SABSI-UTS caused by MRSA more often received inadequate empirical 
treatment compared with those caused by susceptible strains (59.7% vs 23.1%; P < .001). The 30-day case fatality rate was lower in 
patients with SABSI-UTS than in those with SABSI-other (14.4% vs 23.8%; P = .02). Factors independently associated with mor-
tality were dependence for daily activities (aOR, 3.877; 95% CI, 1.08–13.8; P = .037) and persistent bacteremia (aOR, 7.88; 95% CI, 
1.57–39.46; P = .012).
Conclusions. SABSI-UTS occurs predominantly in patients with severe underlying conditions and in those who have under-
gone urinary tract manipulation. Moreover, it is frequently due to MRSA strains and causes significant mortality.
Keywords.  bacteremia; Staphylococcus aureus; urinary devices; urinary tract infection.
Staphylococcus aureus is a leading cause of bloodstream infec-
tion and continues to be associated with high mortality [1–3]. 
A key predictor of mortality in patients with S. aureus bacte-
remia is the source of the infection, with some (eg, endocar-
ditis) considered high-risk and others (eg, catheter-related) 
considered low-risk sources for poor outcomes [2, 4]. These 
risk differences may be associated with the bacterial inoculum 
related to each source and/or with the possibility of achieving 
a prompt source control. Moreover, methicillin resistance has 
been associated with worse outcomes in patients with S. aureus 
bloodstream infection. The mean percentage of methicillin-
resistant S. aureus in the European Union was 16.4% in 2018, al-
though large differences in national percentages were observed, 
with 24% in Spain [5].
S.  aureus bacteriuria is an uncommon finding, accounting 
for only 0.4%–4% of positive urine cultures [6, 7]. Although 
it may only represent urinary tract colonization in asympto-
matic patients, it can also result from hematogenous seeding 
to the urinary tract. Indeed, S. aureus bacteriuria is present in 
about 7%–16% of patients with S. aureus bloodstream infection 
(SABSI), particularly in cases of endocarditis, and is considered 
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a marker of hematogenous seeding to the renal parenchyma 
[7–11]. Alternatively, S.  aureus could be a true urinary path-
ogen among patients residing in long-term care facilities, car-
rying indwelling catheters, with urinary tract obstruction and/
or malignancy, and following instrumentation [6]. These cases 
may therefore have developed an SABSI from an “ascending” 
urinary tract source (UTS) [12].
SABSI from a UTS (ie, SABSI-UTS) is an infrequent com-
plication of urinary tract infections and accounts for only 3% 
to 6% of patients with SABSI [13, 14]. However, interpreting 
the frequency of SABSI-UTS is complicated because of diffi-
culties in attributing an episode of SABSI to a UTS. Although 
the presence of S.  aureus in the urine is important to note, 
this alone is insufficient to diagnose SABSI-UTS [10]. Instead, 
SABSI-UTS should only be considered in patients with 
SABSI, urinary tract symptoms and/or signs, no evidence of 
an extra-urinary source of infection, and an S. aureus count 
≥105 colony-forming units/mL in urine specimen. To date, the 
topic of SABSI-UTS has been largely overlooked, especially 
when using strict criteria [2, 15].
We aimed to improve our knowledge of the characteristics 
and outcomes of SABSI-UTS in a large cohort of clearly defined 
cases managed in 3 university teaching hospitals.
METHODS
Study Design, Setting, and Participants
This was a retrospective cohort analysis of prospectively col-
lected data of adult patients (≥18 years old) with SABSI. Data 
were collected from 1996 to 2018 for 3 tertiary teaching hospitals 
in Spain: Hospital Universitari de Bellvitge, a 700-bed hospital 
for adults in Barcelona; Hospital Universitario 12 de Octubre, a 
1300-bed hospital in Madrid; and Hospital Universitario Virgen 
Macarena, a 960-bed hospital in Seville. Patients with positive 
blood cultures were reported daily by members of the micro-
biology department and were seen and prospectively followed 
up by infectious disease specialists during their hospital admis-
sions. Susceptibility of S.  aureus strains and patient mortality 
were compared between SABSI from UTS (SABSI-UTS) and 
other sources (SABSI-other).
Variables and Data Source
Patients with SABSI were reported daily to the infectious dis-
ease team by members of the microbiology department for 
follow-up. Demographic, epidemiological, clinical, and micro-
biological data were collected from clinical charts for all pa-
tients with SABSI. The following data were recorded: age, sex, 
comorbidities, functional and immunological status, contact 
with the health care system, clinical data at the onset of bacte-
remia, recent procedures (eg, indwelling urinary catheters and/
or urinary manipulation), microbiological reports, diagnostic 
procedures, therapeutic interventions, empirical antimicrobial 
treatment, and outcomes. Follow-up data for up to 30 days after 
the onset of bacteremia were obtained to assess mortality by 
reviewing the patients’ electronic clinical charts. Data were in-
cluded in a database and reviewed retrospectively for the pur-
poses of this study.
Definitions
SABSI was defined as the presence of at least 1 positive blood 
culture obtained in a patient with clinical signs and symptoms 
of infection such as fever, shivering, and/or chills. In addition, 
SABSI-UTS was diagnosed in patients with SABSI by the pres-
ence of urinary tract symptoms and/or signs, the lack of a plau-
sible extra-urinary source of infection, and the presence of an 
S.  aureus count of ≥105 colony-forming units/mL in a urine 
specimen. Urinary symptoms and signs included dysuria, flank 
or suprapubic pain, pyuria, or haematuria. Patients with SABSI 
and orchiepididymitis and/or prostatic abscess, even without a 
positive urine culture, were also included. All possible SABSI-
UTS episodes were reviewed by 3 study investigators who were 
part of a 6-member clinical review panel (SG, GC, IG, JC, EL, 
JA). All members of the panel are specialists in infectious dis-
ease and have extensive clinical experience treating SABSI. The 
reviewers were asked to check the microbiology results and 
baseline urologic comorbidities and to exclude a potential alter-
native source of SABSI. The final decision regarding the inclu-
sion or exclusion of each case was made by consensus.
Infection acquisition was categorized according to Friedman’s 
criteria [16]. The Pitt bacteremia score (Pitt score), a validated 
prognostic mortality factor, was used to assess the severity of 
bacteremia at onset [17]. Sepsis was determined according 
to whether the quick Sequential Organ Failure Assessment 
(qSOFA) score was ≥2 points. Patients with septic shock were 
identified clinically based on the need for vasopressors to main-
tain a mean arterial pressure of ≥65 mmHg and by the presence 
of serum lactate levels >2 mmol/L (>18 mg/dL) in the absence 
of hypovolemia [18].
Echocardiography was performed in patients with persistent 
bacteremia and in those with cardiac anomalies and/or with 
intravascular devices. An empirical antibiotic was defined as 
the antibiotic administered in the first 48 hours after a positive 
blood culture was drawn; it was considered appropriate if the 
strain was susceptible to ≥1 administered antibiotic based on 
current EUCAST breakpoints [19]. Adequate and early con-
trol of the source was considered to have been achieved when 
a drainage procedure was performed in the first 72 hours from 
the onset of SABSI, when this was feasible. Persistent bacte-
remia was defined as a positive blood culture for S. aureus at 
≥3  days after appropriate antimicrobial treatment. Persistent 
positive urine culture was defined as the presence of any re-
peated positive urine culture for S.  aureus during the 30-day 
follow-up. Susceptibility rates of S. aureus strains were obtained 
in cases of SABSI-UTS and SABSI-other.
S. aureus Bacteremic Urinary Tract Infection • ofid • 3
Urinary tract procedures were classified as urethral cath-
eter, ureteral catheter, nephrostomy, urinary diversion, or 
suprapubic cystostomy. Urinary manipulation was considered 
when a patient had undergone urinary tract handling within 
30  days of developing bacteremia. Such procedures included 
urethral catheter insertion or change, nephrostomy, ureteric 
stent, ureterostomy, and urologic surgical procedure.
The Charlson comorbidity score was used to assess the role 
of underlying disease [20]. Dependency was classified as inde-
pendent for daily life activities (ie, supervision or help was not 
essential for activity) or dependent for daily life activities (ie, 
some help was needed daily) [21]. Thirty-day mortality was de-
fined as death due to any cause within 30 days after the onset of 
bacteremia.
Exclusion Criteria
Patients were excluded if urine was not collected for culture, if 
they had negative or no urine culture results, or if ≥2 different 
pathogens were isolated in a urine specimen with no evidence 
of S. aureus. Patients without complete follow-up data were also 
excluded from analysis.
Microbiological Studies
Two sets of blood cultures were collected for each bacteremia 
episode using BD BACTEC PLUS Aerobic/F plus Anaerobic/F 
or Lytic/10 Anaerobic/F mediums. The samples were processed 
in a BD BACTEC FX blood culture system (Becton Dickinson, 
Barcelona, Spain).
Urine samples were plated on CLED agar following standard 
procedures. S. aureus was identified by classical methods (latex 
agglutination and DNase production) or by MALDI-TOF 
(since 2013).
Antimicrobial susceptibility was determined according to 
the EUCAST guidelines by either disk diffusion method (urine 
samples) or microdilution (blood samples) using commercially 
available panels (MicroScan, Beckman Coulter, Barcelona, 
Spain) [19].
Statistical Analysis
All data were analyzed using SPSS software, version 15.0 (SPSS 
Inc., Chicago, IL, USA). Categorical variables are presented as 
number of cases and percentages, while continuous variables are 
presented as means and standard deviations or medians and in-
terquartile ranges (IQRs). Continuous variables were compared 
by Student t tests or Mann-Whitney U tests, as appropriate. The 
Fisher exact test or Pearson’s χ 2 test was used to assess the re-
lationship between categorical variables. Multivariate logistic 
regression analysis was then used to assess the factors poten-
tially associated with 30-day mortality. However, because of 
the low mortality rate, each variable found to be significantly 
associated with 30-day mortality in the univariate analysis was 
ultimately incorporated into multivariate models and adjusted 
by 2 other variables considered strong predictors of mortality 
(age  >70  years and Charlson comorbidity score  >5 points). 
Goodness of fit was assessed by the Hosmer-Lemeshow test. 
Relative risks are expressed as adjusted odds ratios (aORs) and 
95% confidence intervals. Statistical significance was estab-
lished at α = 0.05. All reported P values are 2-tailed.
Ethics
This research and manuscript were reviewed before publica-
tion by the Research Ethics Committee of Bellvitge University 
Hospital. Written informed consent was waived, as it was an 
observational and retrospective analysis of our usual clinical 
practice. All patient data were anonymized for the purpose of 
analysis, and confidential data were protected in accordance 
with appropriate national and European standards.
This paper was written in accordance with the STROBE 
Statement (Supplementary Data).
RESULTS
There were 4181 episodes of SABSI recorded during the study 
period, and of these, 154 (3.68%) were considered to be pos-
sible SABSI-UTS. A  further 22 patients were excluded from 
analysis because they had >2 bacterial strains in urine culture 
(3 patients), no collected or negative urine culture (10 patients), 
or urine culture positive for microorganisms other than S. au-
reus (9 patients). The remaining 132 cases (3.16%) were con-
sidered definite cases of SABSI-UTS and were included in the 
final study (Figure 1).
The baseline characteristics of patients are summarized in 
Table 1. Patients with SABSI-UTS were more frequently men, 
had a mean age of 67 years, and had a median Charlson comor-
bidity score of 5 points, with more severe dependency for daily 
activities. More than 40% of the cohort had solid cancer. The in-
fections were nosocomial or health care–associated in >70% of 
cases, and 11% of patients had orthopedic prostheses or cardiac 
devices in place at the onset of bacteremia. Regarding the base-
line infection severity, 23 patients had a Pitt score of >2 points, 
and 7 patients had septic shock at the onset of bacteremia.
As detailed in Table  2, indwelling urinary devices were 
present in 94 patients (71.2%), 3 patients had urinary diversion, 
and urinary manipulation had been performed before SABSI-
UTS in >60% of patients. Manipulation had been performed 
a median (IQR) of 9 (2–21) days before bacteremia, with ure-
thral catheterization or change of urethral catheters being 
most common, followed by urinary surgical intervention and 
nephrostomy. Figure 2 shows that catheter-associated urinary 
tract infection was the most common infection, followed by as-
cending pyelonephritis and obstructive pyelonephritis.
It was notable that SABSI-UTS was more often caused by 
MRSA strains than SABSI-other (40.9% vs 17.5%; P  <  .001). 
Patients with MRSA infection less frequently received 
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adequate treatment than those with infection from methicillin-
susceptible strains (40.3% vs 76.9%; P < .001). Nineteen patients 
(14.4%) died, of whom 10 had MRSA strains and 9 had sus-
ceptible strains (10 of 54 patients [18.5%] vs 9 of 78 patients 
[11.5%]; P = .261).
Adequate source control within the first 72 hours after 
SABSI-UTS was achieved in 97 patients (73.5%) (Table  3). 
Persistent bacteremia occurred in 9 patients (6.8%). Adequate 
empiric antibiotic treatment and prompt source control were 
associated with lower persistent bacteremia, though without 
reaching statistical significance (4/80 [5%] vs 5/52 [9.6%]; 
P = .247; and 1/41 [2.4%] vs 1/5 [20%]; P = .208; respectively). 
No patient developed metastatic infection or endocarditis 
during follow-up.
The 30-day case fatality rate was lower in patients with 
SABSI-UTS than in those with SABSI-other (19/132 [14.4%] 
vs 963/4049 [23.8%]; P = .02). Table 4 shows the results of the 
univariate and multivariate analyses of factors related to the 
30-day case fatality rate. In the univariate analysis, patients who 
died within 30 days had higher Charlson comorbidity scores, 
were more frequently dependent for activities of daily living, 
had higher Pitt scores, and presented more frequently with per-
sistent bacteremia than surviving patients. After adjustment for 
age >70  years and Charlson comorbidity score >5 points, the 
only risk factors that remained independently associated with 
30-day mortality were dependence on daily activities (aOR, 
3.877; 95% CI, 1.08–13.8; P =  .037) and persistent bacteremia 
(aOR, 7.88; 95% CI, 1.57–39.46; P = .012). Given that very few 
Table 1. Baseline Characteristics of Patients with SABSI-UTS
Variables
Patients With SABSI-UTS  
(n = 132)
Age  
 Mean (SD), y 67.39 (15.60)
 Median (IQR), y 70.0 (57.25–79.85)
Age >65 y 87 (65.9)
Male sex 116 (87.9)
Comorbidity  
 Charlson comorbidity score  
  Mean (SD) 5.14 (2.65)
  Median (IQR) 5 (3–7)
Charlson comorbidity score >5 60 (45.5)
 Dementia/neurologic disorders 21 (15.9)
 Chronic obstructive  
pulmonary disease
21 (15.9)
 Chronic cardiac disorders 22 (16.6)
 Chronic liver disease 14 (10.6)
 Chronic renal impairment 3 (2.27)
 Malignancy 57 (43.2)
 Orthopedic prostheses or  
cardiac devices
14/126 (11.1)
Functional status  
 Dependent for daily living activities 50 (37.9)
Acquisition  
 Nosocomial 52 (39.4)
 Community-acquired 28 (21.2)
 Health care–associated 52 (39.4)
Long-term care facility residents 15 (11.4)
Data are presented as No. (%), unless otherwise specified. 
Abbreviations: CCI, Charlson comorbidity index; IQR, interquartile range; SABSI-UTS, 
Staphylococcus aureus bloodstream infection [from a] urinary tract source.
4181 episodes of  SABSI
154 possible SABSI-UTS
132 SABSI-UTS included
4027 episodes of  SABSI from other sources 
- Pure S.aureus urine culture (n = 119)
- Prostatic abscess or orchiepididymitis without
  collection of  urine sample (n = 5)
- Polymicrobial urine cultures including S. aureus
  (n = 8)
- Negetive urine culture (n = 5)
- Urine culture not collected (n = 5)
- Urine culture contaminated (n = 3)
- Urine culture positive for microorganisms other
   than S. aureus (n=9)
Exclusions:
Figure 1. Study flowchart for the selection of patients with SABSI-UTS. Abbreviation: SABSI-UTS, Staphylococcus aureus bloodstream infection [from a] urinary tract 
source.
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patients with a high Pitt score survived, this variable was ex-
cluded from the multivariate analysis.
DISCUSSION
In our large cohort of well-defined cases, we found that SABSI-
UTS occurs mainly in patients with severe underlying con-
ditions, urinary tract catheterization, and/or urinary tract 
manipulation. Moreover, these infections were frequently 
caused by MRSA strains that were not covered by empirical 
treatment.
It was shown that SABSI-UTS was frequent in men with 
multiple comorbidities, urological malignancy, dependence 
for daily activities, and indwelling urinary catheters, consistent 
with previous research [12]. Urinary catheterization leads to 
an inflammatory response with the induction of fibrinogen re-
lease and deposition on urinary catheters [22]. In vitro and in 
vivo studies suggested that the interaction between S.  aureus 
and fibrinogen could contribute to the development of catheter 
colonization [23, 24], facilitating urinary colonization and sub-
sequent infection.
SABSI-UTS was caused more often by MRSA when com-
pared with SABSI from other sources. This was likely to have 
stemmed from the higher number of cases with nosocomial or 
health care–related bacteremia, the high comorbidity burden, 
the greater dependence on daily activities, and the high pro-
portion of patients coming from nursing homes. The high fre-
quency of MRSA strains is a clinically relevant issue because 
patients with SABSI-UTS due to these strains more often re-
ceived inadequate empirical treatment and had nonsignificant 
Table 2. Urological Characteristics of Patients With SABSI-UTS
Variablesa 
Patients With SABSI-UTS 
(n = 132)
Urological medical records  
 Urological cancer 43 (32.6)
  Bladder cancer 25 (18.9)
  Prostate cancer 10 (7.6)
  Other tumors causing urinary obstruction 8 (6.1)
 Renal or ureteral lithiasis 23 (17.4)
 Neurogenic bladder 12 (9.1)
 Benign prostatic hyperplasia 6 (4.5)
 Renal transplant with ureteral stricture 3 (2.3)
Indwelling urinary catheters 94 (71.2)
 Urethral catheter 52 (39.4)
 Nephrostomy 21 (15.9)
 Ureteric stent 10 (7.6)
 Ureterostomy 7 (5.3)
 Urinary diversion 3 (2.3)
 Suprapubic cystostomy 1 (0.8)
Urinary manipulation 85 (64.4)
 Urethral catheter change 29 (34.11)
 Urinary surgical intervention 20 (23.5)
 Nephrostomy 18 (21.2)
 Ureteral stent change/insertion 8 (9.4)
 Urinary diversion 7 (8.8)
 Prostatic/renal biopsy 3 (3.5)
Time from manipulation to bacteremia  
 Mean (SD), d 15.2 (20)
 Median (IQR), d 9 (2–21)
Data are presented as No. (%), unless otherwise specified. 
Abbreviations: IQR, interquartile range; SABSI-UTS, Staphylococcus aureus bloodstream 






















Figure 2. Diagnosis of urinary tract infection. Abbreviation: SABSI-UTS, Staphylococcus aureus bloodstream infection [from a] urinary tract source.
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but higher 30-day case fatality rates compared with patients 
who had SABSI-UTS caused by susceptible strains. Urinary 
gram staining is a rapid, easy, and cheap diagnostic method 
that is underused at the moment, but it could help to deter-
mine if S. aureus coverage is suitable (including therapy for 
MRSA strains) when SABSI-UTS is suspected [25]. In addi-
tion, checking for prior MRSA colonization could help when 
choosing the best antimicrobial treatment, particularly in pa-
tients presenting with septic shock.
The 30-day case fatality rate of 14.4% in our cohort of pa-
tients with SABSI-UTS was similar to that previously reported 
[26]. Although was high, it was lower than that documented 
for SABSI from all sources, which was estimated to be 23.8%. 
We find that there were 4 main reasons for the lower mortality 
observed in patients with SABSI-UTS. First, the presence of 
urinary signs and symptoms makes the diagnosis of a urinary 
tract infection easier to establish, thereby triggering prompt 
antibiotic treatment that can offer gram-positive coverage in 
most cases. Second, compared with other sources of infec-
tion, SABSI-UTS was more frequently nosocomial or health 
care–associated, carrying a lower mortality than community-
acquired infections. Third, compared with other sources of 
infection, septic shock was observed less frequently at pres-
entation with SABSI-UTS [4]. Fourth, the urinary tract can 
be easily drained, facilitating source control and preventing 
persistent bacteremia. In fact, persistent bacteremia was less 
frequent in our cohort than in other series of overall SABSI, 
where data indicate rates as high as 30% of cases [27]. We 
therefore conclude that SABSI-UTS has a low mortality risk 
among sources of SABSI, as long as urinary tract infection is 
correctly diagnosed and asymptomatic bacteriuria secondary 
to SABSI from other sources has been ruled out. Nevertheless, 
it should be noted that the 30-day case fatality rate was higher 
for SABSI-UTS than was reported elsewhere for complicated 
urinary tract infection caused by other microorganisms (14.4 
vs 8.7%; P < .001) [28].
In our study, the risk factors associated with 30-day mortality 
were a high burden of comorbidities, poor functional status, 
high illness severity at presentation, and persistent bacteremia. 
However, we did not find a statistically significant relationship 
between mortality and other well-described predictive factors, 
such as the presence of MRSA, treatment with adequate empir-
ical antibiotics, or early source control. This could be due to the 
small sample size and number of deaths, which made it difficult 
to show statistical differences between groups.
The multicenter nature and inclusion of the largest cohort of 
well-defined SABSI-UTS cases are important strengths of this 
study, but several limitations should also be acknowledged. 
Table 4. Univariate and Multivariate Analysis Related to 30-Day Case Fatality Rate
Variable Dead Within 30 Days (n = 19) Alive at 30 Days (n = 113) P Value OR 95% CI P Value
Age >70 y 13 (68.4) 55 (48.7) .111    
Charlson comorbidity score >5 15 (78.9) 45 (39.8) .002    
Pitt score >2 6 (31.6) 2 (1.8) .000    
Malignancy 10 (52.6) 45 (40.2) .309 1.06 0.387–3.105 .863
Dependent for activities of daily living 14 (73.7) 36 (31.9) .001 3.877 1.089–13.806 .037
Methicillin-resistant Staphylococcus aureus 10 (52.6) 44 (38.9) .261 1.474 0.513–4.238 .472
Adequate empiric antibiotic treatment 13 (68.4) 67 (59.3) .451 0.550 0.181–1.670 .291
Persistent bacteremia 4 (21.1) 5 (4.4) .025 7.884 1.575–39.469 .012
Early source control 12 (63.2) 85 (75.2) .270 0.641 0.215–1.911 .425
Data are presented as No. (%), unless otherwise specified. The multivariate regression was adjusted for age >70 and Charlson comorbidity score >5.
Abbreviation: OR, odds ratio.
Table 3. Microbiological and Clinical Data
Variablesa
Patients With SABSI-UTS 
(n = 132)
Microbiological data  
 Polymicrobial bacteremiaa 13 (9.8)
 Methicillin-resistant Staphylococcus aureus 54 (40.9)
Clinical data  
 Urinary symptoms 76 (57.6)
 Pyuria 51 (38.6)
 Hematuria 30 (22.7)
 Fever 118 (89.4)
Baseline illness severity  
 Pitt score ≥2 23 (17.4)
 Septic shock 7 (5.3)
 ICU admission 7 (5.3)
Infection management  
 Source control <72 h 97 (73.5)
 Adequate empiric antibiotic treatment 80 (60.6)
 Echocardiography 40 (30.3)
Persistent positive urine culture 3 (2.3)
Persistent bacteremia 9 (6.8)
30-d case fatality rate 19 (14.4)
Data are presented as No. (%), unless otherwise specified. 
Abbreviations: ICU, intensive care unit; SABSI-UTS, Staphylococcus aureus bloodstream 
infection [from a] urinary tract source.
aPolymicrobial bacteremia: Pseudomonas aeruginosa (3, 2.3%), Escherichia coli (2, 1.5%), 
Enterococcus faecalis (2, 1.5%), Enterobacter cloacae (2, 1.5%), Proteus mirabilis (1, 
0.75%), Bacteroides fragilis (1, 0.75%), Streptococcus anginosus (1, 0.75%), Candida 
glabrata (1, 0.75%).
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Although patients were followed prospectively by infectious 
diseases specialists, and although the data were collected pro-
spectively, the main limitation is that this was a retrospectively 
designed study. To overcome this, patients were selected ac-
cording to clear criteria, and all cases were reviewed by a panel 
of infectious diseases specialists. Patients with no obvious uri-
nary tract infection were excluded from analysis, as were pa-
tients in whom a different source of infection was possible. We 
also needed to exclude some patients with no urine sample 
for culture, and this could have led to an underestimation of 
the true number of episodes. Another important limitation 
was that few episodes of SABSI-UTS were included despite 
the multicenter design, and this made it difficult to carry out 
and interpret the multivariate analyses. This study also suffers 
from the lack of a comparison group. Finally, we acknowl-
edge that, in spite of an intensive review, it is often difficult 
to discern the source of SABSI, so it is still possible that pa-
tients’ urinary symptoms were due to high-grade SABSI from 
a different source.
In conclusion, SABSI-UTS occurs mostly in patients with se-
vere underlying conditions, urinary tract catheterization, and 
urinary tract manipulation, consistent with existing calls to 
avoid unnecessary catheterization when trying to prevent uri-
nary tract infections. SABSI-UTS caused significant mortality, 
and MRSA strains were identified in a large number of cases. 
Thus, it could be useful to perform urine gram stain and to as-
sess previous MRSA colonization to improve empirical antibi-
otic treatment. In settings with MRSA prevalence comparable 
to (or higher than) that observed in Spain, physicians should 
consider MRSA coverage when deciding on the choice of em-
pirical therapy for suspected urinary tract infection in patients 
with possible SABSI-UTS, particularly among those with a his-
tory of MRSA colonization.
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